Latest filing published 29 Nov 2012 for Zivo Bioscience, Inc., €419.
Insider track record
No signal scores available.
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +133.3%Entry US$57.60 · Close at T+365 US$134.40
- +163.6%Entry US$52.80 · Close at T+365 US$139.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Andrew A. Dahl: trading record in brief
This profile gathers the share dealings of Andrew A. Dahl in Zivo Bioscience, Inc. Over a trading history stretching from 16 December 2011 to 28 November 2012, the count stands at 3 filings.
Every open-market trade on record is a purchase: 2 purchases worth €8,341, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant. So far in 2012, the count stands at 2 purchases and no sales.
The newest entry dates from 29 November 2012: an open-market purchase of €419, in Zivo Bioscience, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Andrew A. Dahl
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$0.1083Common StockSEC:0001078782-12-003040:0Canonical exit: 26 Feb 2013 (T+90)
- 95,000 shares@ US$0.1083Common StockSEC:0001078782-12-003015:0Canonical exit: 25 Feb 2013 (T+90)
- 1,458,232 shares@ US$0.19Common StockSEC:0001078782-11-003693:0
3 of 3 declarations
